What are the preferred single-agent antimetabolite regimens for the treatment of recurrent or metastatic breast cancer?

Updated: Apr 23, 2020
  • Author: Joseph A Sparano, MD; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print


Regimens are as follows:

  • Capecitabine 1000-1250 mg/m 2 PO BID on days 1-14 every 3 wk [38] or
  • Gemcitabine 800-1200 mg/m 2 IV on days 1, 8, and 15 every 4 wk

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!